相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity
George L. Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation
Robert J. Soiffer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial
Juergen Finke et al.
LANCET HAEMATOLOGY (2017)
Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome
D. Modi et al.
BONE MARROW TRANSPLANTATION (2017)
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial
Irwin Walker et al.
LANCET ONCOLOGY (2016)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
Madan H. Jagasia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT
V. Ratanatharathorn et al.
BONE MARROW TRANSPLANTATION (2015)
Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease
Raynier Devillier et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation
F. Baron et al.
BONE MARROW TRANSPLANTATION (2014)
A disease risk index for patients undergoing allogeneic stem cell transplantation
Philippe Armand et al.
BLOOD (2012)
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT
R. Devillier et al.
BONE MARROW TRANSPLANTATION (2012)
Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation
Mark Bosch et al.
CYTOTHERAPY (2012)
Fludarabine, Antithymocyte Globulin, and Very Low-Dose Busulfan for Reduced-Intensity Conditioning before Allogeneic Stem Cell Transplantation in Patients with Lymphoid Malignancies
Florent Malard et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission
Sherif S. Farag et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies
Robert J. Soiffer et al.
BLOOD (2011)
TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions
C. E. Hill-Kayser et al.
BONE MARROW TRANSPLANTATION (2011)
The Addition of 400 cGY Total Body Irradiation to a Regimen Incorporating Once-Daily Intravenous Busulfan, Fludarabine, and Antithymocyte Globulin Reduces Relapse Without Affecting Nonrelapse Mortality in Acute Myelogenous Leukemia
James A. Russell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Allogeneic stem cell transplantation for acute myeloid leukemia
Jacopo Peccatori et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia
Boglarka Gyurkocza et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation for Hematologic Malignancies
Mehdi Hamadani et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
Juergen Finke et al.
LANCET ONCOLOGY (2009)
Polyclonal Rabbit Antithymocyte Globulin Exhibits Consistent Immunosuppressive Capabilities Beyond Cell Depletion
Gina LaCorcia et al.
TRANSPLANTATION (2009)
Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction:: Disruption of immunological synapse and conjugate formation
Michael Haidinger et al.
TRANSPLANTATION (2007)
Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation
A Bacigalupo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older
V Gupta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older
H Wallen et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age
EP Alyea et al.
BLOOD (2005)
Acute and chronic Graft-versus-Host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation
DR Couriel et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2004)
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years
R Wong et al.
BLOOD (2003)
分享论文
